Tozasertib (VX-680, MK-0457)

Name: Tozasertib (VX-680, MK-0457)
Brand: Selleck Chemicals
SKU: S1048
Rating: 5 (96 reviews)

For research use only.

Catalog No.S1048

96 publications

Tozasertib (VX-680, MK-0457) Chemical Structure

CAS No. 639089-54-6

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with K_i_app of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. The only exceptions are Fms-related tyrosine kinase-3 (FLT-3) and BCR-ABL tyrosine kinase, which are inhibited by the Tozasertib with both Ki of 30 nM. Tozasertib induces apoptosis and autophagy. Phase 2.

Selleck's Tozasertib (VX-680, MK-0457) has been cited by 96 publications

Nature, 2018, 559(7713):211-216.

PubMed: 29973724 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Cell, 2010, 6;142(3):444-55.

PubMed: 20691903 ( click the link to review the publication )

J Cell Biol, 2021, 220(2)e202008029

PubMed: 33355621 ( click the link to review the publication )

PLoS Biol, 2021, 19(1):e3001029

PubMed: 33395410 ( click the link to review the publication )

J Clin Invest, 2020, 139080

PubMed: 33016928 ( click the link to review the publication )

EMBO Rep, 2020, 3;21(4):e49700

PubMed: 32030856 ( click the link to review the publication )

Cancer Res, 2020, 80(18):3841-3854

PubMed: 32690724 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2697

PubMed: 32967224 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(4):1008-1017

PubMed: 31848297 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Toxicol Sci, 2020, kfaa103

PubMed: 32617558 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Death Differ, 2019, 26(3):548-564

PubMed: 30050055 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31652588 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):432

PubMed: 31160567 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):390-399.e5

PubMed: 30612951 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )
Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Analyst, 2019, 145(1):97-106

PubMed: 31746831 ( click the link to review the publication )

J Pharm Biomed Anal, 2019, doi: 101016/jjpba2019112962

PubMed: 31711864 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2019, 41(6):e359-e370

PubMed: 30702467 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Cell Signal, 2018, 52:137-146

PubMed: 30223016 ( click the link to review the publication )

SLAS Discov, 2018, 23(2):132-143

PubMed: 28957641 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):1004-1010

PubMed: 30080692 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29560108 ( click the link to review the publication )

Neuron, 2017, 94(6):1142-1154

PubMed: 28641113 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Cancer Res, 2017, 77(2):494-508

PubMed: 28069801 ( click the link to review the publication )

Oncogene, 2017, 36(44):6177-6189

PubMed: 28869606 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

EMBO J, 2016, 35(8):803-19

PubMed: 26929011 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(50):14366-14371

PubMed: 28182563 ( click the link to review the publication )

Elife, 2016, 5:e11402

PubMed: 26878753 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )
Exp Cell Res, 2016, 344(2):153-66

PubMed: 27138904 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):819-26

PubMed: 27373675 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(1):212-8

PubMed: 27003257 ( click the link to review the publication )

Exp Hematol, 2016, 44(3):189-93

PubMed: 26706195 ( click the link to review the publication )

Tumour Biol, 2016, 37(11):14745-14755

PubMed: 27629142 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26580-92

PubMed: 27058891 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(23):5338-48

PubMed: 26152738 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(2):419-28

PubMed: 25522764 ( click the link to review the publication )

Oncol Rep, 2015, 34(2):803-10

PubMed: 26044736 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0134306

PubMed: 26218638 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(6):1354-64

PubMed: 25873592 ( click the link to review the publication )

J Mol Cell Biol, 2014, 6(3):240-54

PubMed: 24847103 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(5):934-44

PubMed: 24480460 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2014, 307(2):L173-85

PubMed: 24838752 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

Oncol Lett, 2014, 7(1):121-124

PubMed: 24348832 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7498-511

PubMed: 25115395 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )
Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Arthritis Rheum, 2013,

PubMed: 23653330 ( click the link to review the publication )

Mol Cancer Res, 2013, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(11):1326-36

PubMed: 24008673 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1235-46

PubMed: 23321637 ( click the link to review the publication )

J Cell Mol Med, 2013, 17(2):265-76

PubMed: 23301855 ( click the link to review the publication )

Vet Comp Oncol, 2013, 10.1111/vco.12018

PubMed: 23410058 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23328114 ( click the link to review the publication )

Eur J Cancer, 2012, 48(15):2417-30

PubMed: 22244830 ( click the link to review the publication )

Oncogene, 2012, 31(31):3584-96

PubMed: 22120720 ( click the link to review the publication )

J Med Chem, 2012, 55(17):7392-416

PubMed: 22803810 ( click the link to review the publication )

Brain Pathol, 2012, 23(3):244-53

PubMed: 22971244 ( click the link to review the publication )

J Neurosci, 2012, 32(32):11050-66

PubMed: 22875938 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1217-28

PubMed: 22306067 ( click the link to review the publication )

Biochem J, 2012, 447(1):93-102

PubMed: 22784093 ( click the link to review the publication )

Exp Cell Res, 2012, 318(4):336-49

PubMed: 22197704 ( click the link to review the publication )

Cytoskeleton, 2012, 69(10):840-53

PubMed: 22887753 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Curr Biol, 2011, 21(16):1356-65

PubMed: 21820309 ( click the link to review the publication )

Cancer Res, 2011, 71(23):7207-15

PubMed: 21978935 ( click the link to review the publication )

J Biol Chem, 2011, 286(42):36304-15

PubMed: 21878642 ( click the link to review the publication )

Biochem J, 2011, 440(1):85-93

PubMed: 21774789 ( click the link to review the publication )

Mol Cancer Ther, 2010, 9(5):1318-27

PubMed: 20388735 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description

Targets

Aurora A ^[1] (Cell-free assay)	Aurora C ^[1] (Cell-free assay)	Aurora B ^[1] (Cell-free assay)	FLT3 ^[4] (Cell-free assay)	Bcr-Abl ^[4] (Cell-free assay)
0.6 nM(Ki app)	4.6 nM(Ki app)	18 nM(Ki app)	30 nM(Ki)	30 nM(Ki)

In vitro

Although its multi-kinase profile, VX-680 induces similar cytotoxicity with IC50 of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. VX-680 prevents the CAL-62 proliferation in a time-dependent manner. VX-680 treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibits proliferation with the IC50 between 25 and 150 nM. The VX-680 significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that VX-680 induces apoptosis in the different cell lines. CAL-62 cells exposed for 12 hours to VX-680 showed an accumulation of cells with ≥4N DNA content. Time-lapse analysis demonstrates that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following VX-680 treatment. ^[2] VX-680 has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BE-13	MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlf5TWM2OD1yLkCwN\|M5KM7:TR?=	NWT3W5FWW0GQR2LFVi=>
RS4-11	NFexUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwMEC0NFQh\|ryP	M4qw[3NCVkeURWK=
MFH-ino	NEXLUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMEC5PUDPxE1?	NXS0RpQ4W0GQR2LFVi=>
NTERA-S-cl-D1	M4HENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\qTWM2OD1yLkCxOFM1KM7:TR?=	MX7TRW5IWkWU
697	NGDPSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPUTWM2OD1yLkCyOFcyKM7:TR?=	MUPTRW5IWkWU
NALM-6	M13FbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwMEK1OVIh\|ryP	MlHPV2FPT1KHUh?=
ES8	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHkTWM2OD1yLkC0OlE{KM7:TR?=	M1rmbHNCVkeURWK=
HUTU-80	NH7wWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2n2dmlEPTB;MD6wOVI6QSEQvF2=	NVfHZmNSW0GQR2LFVi=>
MV-4-11	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzUcnBkUUN3ME2wMlA4Pzh{IN88US=>	MWnTRW5IWkWU
MONO-MAC-6	NUXVT3V6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwMEe4O\|kh\|ryP	M4jTR3NCVkeURWK=
LC-2-ad	M4qxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGWzNZhKSzVyPUCuNFg4QDlizszN	M13SVnNCVkeURWK=
BL-41	M{nyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYf0OVdKUUN3ME2wMlExPDR3IN88US=>	M3zwfnNCVkeURWK=
A4-Fuk	NEnMN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMUG1OlMh\|ryP	M3vWN3NCVkeURWK=
SW954	M2DCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjwTWM2OD1yLkGyNlI6KM7:TR?=	MWLTRW5IWkWU
BV-173	M3;ON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHmxZXpKSzVyPUCuNVI3PDFizszN	MmnUV2FPT1KHUh?=
TE-11	NVy1emgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjTenVKSzVyPUCuNVQ6QDJizszN	M4\iU3NCVkeURWK=
SK-UT-1	NVv6NJVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\hXId{UUN3ME2wMlE2QTZ3IN88US=>	MlzVV2FPT1KHUh?=
SIG-M5	M33kcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7MRXZKSzVyPUCuNVY4ODdizszN	MVLTRW5IWkWU
OCUB-M	NH\3WZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LONGlEPTB;MD6xOlk5OyEQvF2=	NYTGd2FNW0GQR2LFVi=>
K052	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFW1RpNKSzVyPUCuNVk1QCEQvF2=	MoXmV2FPT1KHUh?=
VA-ES-BJ	NEjremRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\0U2lEPTB;MD6yNFA5PiEQvF2=	NHrqSm9USU6JUlXS
SW982	NG\3Z5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUm3XXJrUUN3ME2wMlIyOzhizszN	MkLRV2FPT1KHUh?=
LB647-SCLC	NUjrbHN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\FTWM2OD1yLkKxOVI{KM7:TR?=	M1O2THNCVkeURWK=
PSN1	NWnsbYQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPyc4RKSzVyPUCuNlIxOjZizszN	Mor2V2FPT1KHUh?=
BB30-HNC	NF\3bYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHZTWM2OD1yLkKyOVkyKM7:TR?=	NIjrXWpUSU6JUlXS
ST486	NG\XemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnH1TWM2OD1yLkKzNFg4KM7:TR?=	Ml7MV2FPT1KHUh?=
MOLT-4	NHzqZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMkOzN\|ch\|ryP	MmLHV2FPT1KHUh?=
EW-16	NHnwd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjHc4VMUUN3ME2wMlI{PzZ6IN88US=>	NX7SVGtzW0GQR2LFVi=>
KS-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMkO3PFUh\|ryP	M2KzXnNCVkeURWK=
SR	M1i5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XCd2lEPTB;MD6yOFU3PCEQvF2=	M133bHNCVkeURWK=
KM12	MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHr3eY1KSzVyPUCuNlY{PiEQvF2=	NVTjVmlmW0GQR2LFVi=>
EM-2	NHLwVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\OdWlEPTB;MD6yOlY1OSEQvF2=	MmPxV2FPT1KHUh?=
MEG-01	NHr4NZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVj0[GZ1UUN3ME2wMlI4QDR7IN88US=>	M1PaVnNCVkeURWK=
NB13	NXXOTJNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDoTWM2OD1yLkK3PVg1KM7:TR?=	M{G0fXNCVkeURWK=
RKO	NWfjblB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfsb5V7UUN3ME2wMlMxQDF\|IN88US=>	M4jLeHNCVkeURWK=
CESS	NWC3NZk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDKTWM2OD1yLkOxN\|I5KM7:TR?=	NY\2WlVTW0GQR2LFVi=>
EoL-1-cell	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPoUlBlUUN3ME2wMlM{PDV7IN88US=>	MYXTRW5IWkWU
DOHH-2	NHW5OpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwM{O3PFEh\|ryP	M4nucnNCVkeURWK=
A388	NVq2[ItMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwM{SwPFYh\|ryP	MmTJV2FPT1KHUh?=
LAMA-84	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUT6NlNHUUN3ME2wMlM2OTd6IN88US=>	M3O5SnNCVkeURWK=
IMR-5	NIK2SnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrxTWM2OD1yLkO1OVQh\|ryP	MX\TRW5IWkWU
KARPAS-422	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LDRmlEPTB;MD6zO\|I4OiEQvF2=	MXzTRW5IWkWU
MRK-nu-1	M3SwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwM{ixN{DPxE1?	NGTNOY5USU6JUlXS
BL-70	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDlT5JDUUN3ME2wMlM5QTd2IN88US=>	NELYe3lUSU6JUlXS
LXF-289	M2X4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rMe2lEPTB;MD60NFQxPiEQvF2=	NEHLT\|JUSU6JUlXS
RL95-2	NXvwW3p[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvVRphKSzVyPUCuOFA2PjdizszN	NXThNItuW0GQR2LFVi=>
QIMR-WIL	M1z2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXL4VHczUUN3ME2wMlQzPjd4IN88US=>	M4DUfXNCVkeURWK=
K-562	NHz6UJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkmzTWM2OD1yLkSzOFczKM7:TR?=	M3nRXXNCVkeURWK=
NCI-H510A	NWnROGs5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2X1e2lEPTB;MD60N\|gzOyEQvF2=	MUPTRW5IWkWU
NCI-H524	MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwNUGxOFch\|ryP	NF7JPGtUSU6JUlXS
KE-37	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3S0[mlEPTB;MD61NlExOiEQvF2=	NUnRTYhLW0GQR2LFVi=>
KP-N-YS	NYr6ZlhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjhZVdKSzVyPUCuOVQ{QTJizszN	NWW3cow3W0GQR2LFVi=>
LS-411N	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjvW4ZCUUN3ME2wMlU4PzV{IN88US=>	M{n4SnNCVkeURWK=
CTV-1	MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwNUi3O\|Mh\|ryP	MVjTRW5IWkWU
NCI-SNU-16	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnBbpplUUN3ME2wMlY{PTdzIN88US=>	NXnFV41GW0GQR2LFVi=>
HT-144	M4HmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwNkO3PVgh\|ryP	NX\LNGJmW0GQR2LFVi=>
NCI-H187	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\oS2lEPTB;MD62OFE{KM7:TR?=	NHzFb4hUSU6JUlXS
OCI-AML2	M{LWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHJTWM2OD1yLk[0OFA{KM7:TR?=	MYXTRW5IWkWU
CCRF-CEM	MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrncZpqUUN3ME2wMlY2OzR4IN88US=>	M4HweHNCVkeURWK=
ONS-76	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDL[o5KSzVyPUCuOlY1PThizszN	M{TreHNCVkeURWK=
IST-SL2	M{LHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37CT2lEPTB;MD63NVk5OiEQvF2=	NVPFOmp[W0GQR2LFVi=>
NB6	MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYj1WWVFUUN3ME2wMlc4OjV2IN88US=>	Mkn3V2FPT1KHUh?=
SK-PN-DW	MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIWwOY9KSzVyPUCuO\|kyPCEQvF2=	NU\I[INnW0GQR2LFVi=>
HCC1599	NWHIU3BFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rINGlEPTB;MD64NFg4PCEQvF2=	NH\ibGxUSU6JUlXS
MC116	Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwOEWwNVEh\|ryP	NFzZO5hUSU6JUlXS
TE-15	M4r1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvnTWM2OD1yLki1NFk5KM7:TR?=	MlrEV2FPT1KHUh?=
HOP-62	NVfweJg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DJR2lEPTB;MD64OlMzQSEQvF2=	MonzV2FPT1KHUh?=
TGBC24TKB	NUnZXXdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfjTWM2OD1yLki2N\|g2KM7:TR?=	M3\lc3NCVkeURWK=
HCE-4	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrBVVFCUUN3ME2wMlg5ODZ\|IN88US=>	Ml;1V2FPT1KHUh?=
ALL-PO	MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXiyNJNVUUN3ME2wMlg5OTd3IN88US=>	MYjTRW5IWkWU
KGN	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjBTWM2OD1yLki5PVk2KM7:TR?=	M33zPXNCVkeURWK=
ML-2	MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M12xSWlEPTB;MD65NFI2QSEQvF2=	NXO3XW5RW0GQR2LFVi=>
ES4	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwOUGxNlgh\|ryP	NIrydHNUSU6JUlXS
SF126	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3u3emlEPTB;MD65OFgyQSEQvF2=	M1jpenNCVkeURWK=
SK-N-DZ	MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDUTWM2OD1yLkm2NVg6KM7:TR?=	M{TuSXNCVkeURWK=
HCC1187	NYe2T\|hWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTq[WVLUUN3ME2xMlAxPTB3IN88US=>	MXTTRW5IWkWU
DU-4475	M1H2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\POlZKSzVyPUGuNFE4PTZizszN	M2nTNXNCVkeURWK=
NKM-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYewOFNOUUN3ME2xMlAzPzd3IN88US=>	MUPTRW5IWkWU
HL-60	MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLneFhKSzVyPUGuNFY2PzRizszN	M1;CVHNCVkeURWK=
SBC-1	NXi4d2Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTFwMUK1OFIh\|ryP	NWPzTmlHW0GQR2LFVi=>
TE-10	NEjWXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DkV2lEPTB;MT6xNlk1PiEQvF2=	MUTTRW5IWkWU
ETK-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInaWZlKSzVyPUGuNVM3OTNizszN	NH7Dd4tUSU6JUlXS
HAL-01	MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXvNHlKSzVyPUGuNVY4ODlizszN	NHjFV4hUSU6JUlXS
BB65-RCC	MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\MTWM2OD1zLkG4NFA2KM7:TR?=	NXr0cXNkW0GQR2LFVi=>
EW-1	NX\EdGxMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DDVmlEPTB;MT6xPFU3OiEQvF2=	M3v0O3NCVkeURWK=
SK-NEP-1	MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\2dnN[UUN3ME2xMlIyOTFzIN88US=>	MV\TRW5IWkWU
SK-LMS-1	MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjmbnB7UUN3ME2xMlIzOjF{IN88US=>	NYe0U4Q{W0GQR2LFVi=>
DEL	M1HKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfj[WtEUUN3ME2xMlI2PjR\|IN88US=>	M1u2bnNCVkeURWK=
GT3TKB	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTFwMkiwOVch\|ryP	MUfTRW5IWkWU
MOLT-16	MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLneHBKSzVyPUGuN\|U1ODVizszN	MoXmV2FPT1KHUh?=
CMK	NIjJeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jPSGlEPTB;MT60NlEyPyEQvF2=	NGLHPGxUSU6JUlXS
NB5	NIHre5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPPfphbUUN3ME2xMlY1OjJ7IN88US=>	M33kSnNCVkeURWK=
NCI-H1963	NEHOb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWf5[VNQUUN3ME2xMlcxPTh\|IN88US=>	MWPTRW5IWkWU
KURAMOCHI	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHyyVVBKSzVyPUGuO\|g6OTFizszN	MoT4V2FPT1KHUh?=
TE-8	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTEUWhKSzVyPUGuPFA{PjhizszN	NHz2OmpUSU6JUlXS
NCI-H1304	NFfUN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LC[WlEPTB;MT64N\|A4OyEQvF2=	M4q2ZXNCVkeURWK=
A101D	NFXQcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvCWmdvUUN3ME2xMlg4Ozl3IN88US=>	NHzDWXVUSU6JUlXS
SCLC-21H	M1G3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLjenoyUUN3ME2xMlk4ODV5IN88US=>	MVzTRW5IWkWU
GB-1	MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTJwMEG2OFch\|ryP	NVLLSIxqW0GQR2LFVi=>
KARPAS-45	NIG1VVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3L3Z2lEPTB;Mj6wNlY2PCEQvF2=	MVLTRW5IWkWU
ATN-1	NHjpbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjPe49KSzVyPUKuNFI5PThizszN	M4HnT3NCVkeURWK=
NCI-H720	NH\GbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT6R2ZDUUN3ME2yMlA3OjR2IN88US=>	MX7TRW5IWkWU
RPMI-6666	NH[2ZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\tTWM2OD1{LkG2NlA4KM7:TR?=	M3fZVnNCVkeURWK=
NB17	MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;3SIRPUUN3ME2yMlI6OjdizszN	MlrNV2FPT1KHUh?=
IST-SL1	M{HneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7QcYN4UUN3ME2yMlI6PzZ3IN88US=>	MWnTRW5IWkWU
SH-4	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LsXGlEPTB;Mj6zNlQ3QSEQvF2=	MYTTRW5IWkWU
K5	NVOzZoNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\RSW9KSzVyPUKuOFA{OTlizszN	Mo[3V2FPT1KHUh?=
OVCAR-4	M4f2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnPRYlIUUN3ME2yMlQ3OTNizszN	MWnTRW5IWkWU
ACN	MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHSXlNKSzVyPUKuOVAzOTNizszN	MXrTRW5IWkWU
TGW	NGfSUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYKyPWFNUUN3ME2yMlY2QDN{IN88US=>	MXzTRW5IWkWU
NCI-H2107	NWnwdHVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmi1TWM2OD1{LkizO\|EyKM7:TR?=	M1XRVnNCVkeURWK=
NCI-H82	M3r2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjId4xXUUN3ME2yMlg{QDN6IN88US=>	MXLTRW5IWkWU
SK-N-FI	NH3meXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jSXmlEPTB;Mj64Olg3QCEQvF2=	NY\Sd5lmW0GQR2LFVi=>
LB1047-RCC	M2O5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDQXo5yUUN3ME2yMlg5OTJ4IN88US=>	MUTTRW5IWkWU
LU-134-A	NX;JOllNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHsU3ZKSzVyPUKuPFkzPiEQvF2=	NEjwNWxUSU6JUlXS
NCI-H209	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Xj[GlEPTB;Mj65NVI2OyEQvF2=	MXvTRW5IWkWU
NOMO-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFv3XYtKSzVyPUOuNFIzPzRizszN	NH\1OG5USU6JUlXS
RH-1	NVjZfGlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;kTWM2OD1\|LkG3NlkyKM7:TR?=	NEDqXnRUSU6JUlXS
LOUCY	NHP3RWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPCOJJKSzVyPUOuNVg3QTNizszN	NHfobnZUSU6JUlXS
TE-9	M37VdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4P1PGlEPTB;Mz6yOlc{PiEQvF2=	NVPBTVVxW0GQR2LFVi=>
PF-382	NXHwRW5pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTNwM{W3O\|gh\|ryP	Mk\qV2FPT1KHUh?=
RPMI-8402	M1HLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTNwNUi2NFMh\|ryP	MWXTRW5IWkWU
HEL	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rTOWlEPTB;Mz62N\|Ih\|ryP	NF;CUW5USU6JUlXS
NOS-1	M{XzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fFSmlEPTB;Mz64OFc2PCEQvF2=	NWDSWWNxW0GQR2LFVi=>
ES1	MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIThRpBKSzVyPUOuPVIzQTNizszN	MUTTRW5IWkWU
NCI-H2171	M2jGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTaTWM2OD1\|LkmyOFI{KM7:TR?=	M2jtXnNCVkeURWK=
NCI-H747	M2Tj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH21TmhKSzVyPUOuPVQzOjFizszN	NHjXUXFUSU6JUlXS
MHH-NB-11	NVLZdFR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPPNmdKSzVyPUOuPVU{OTJizszN	NGrMdlRUSU6JUlXS
MZ1-PC	NFH1ZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrFRohKSzVyPUOuPVkzPCEQvF2=	M4LFR3NCVkeURWK=
MMAC-SF	M2nvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HV[GlEPTB;ND6wNlQ3PyEQvF2=	M1zocnNCVkeURWK=
NMC-G1	M3nwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfSTWM2OD12LkKyO\|I{KM7:TR?=	NWjYV3V5W0GQR2LFVi=>
SW872	NF34[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYGxWWx5UUN3ME20MlM1OzRizszN	M1fzUHNCVkeURWK=
TE-12	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7UTWM2OD12LkW2N\|k1KM7:TR?=	MkfxV2FPT1KHUh?=
LU-139	NY\CPIUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PNVmlEPTB;ND62NVg{PSEQvF2=	NUnLfmlyW0GQR2LFVi=>
HC-1	NEPyRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXGeGQ5UUN3ME20MlY6PDl2IN88US=>	NGTxdWVUSU6JUlXS
COR-L279	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1O5UGlEPTB;ND63OVg6OSEQvF2=	NUPSfGFsW0GQR2LFVi=>
SF268	MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjIZ5VKUUN3ME20Mlc6QTF4IN88US=>	MVHTRW5IWkWU
MC-CAR	M3nzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHrTWM2OD13LkC2O\|U4KM7:TR?=	MWfTRW5IWkWU
TK10	M3W5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\QS2JKSzVyPUWuN\|U1PjlizszN	NXy3WlNOW0GQR2LFVi=>
TE-1	M1XNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\lO2lEPTB;NT60PVAxPCEQvF2=	MkDBV2FPT1KHUh?=
NCI-H2126	M3zhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLQZXMxUUN3ME21MlY1PTd2IN88US=>	M2fn[XNCVkeURWK=
Daudi	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLQTWM2OD13Lk[5NVIh\|ryP	M2C1fXNCVkeURWK=
NCI-H1648	MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLDVZlNUUN3ME21MlgyPDV2IN88US=>	NF7iUGZUSU6JUlXS
OS-RC-2	MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfYOIpKSzVyPUWuPVg2QTdizszN	M{KzN3NCVkeURWK=
DJM-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3VTWM2OD14LkO0OlY3KM7:TR?=	NXzPVWFUW0GQR2LFVi=>
LS-1034	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTZwN{W2OkDPxE1?	NFfLTIhUSU6JUlXS
NCI-H1581	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;JSWlEPTB;Nj63PFQxPSEQvF2=	NX\hTYlFW0GQR2LFVi=>
UACC-257	NHW5UYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\iRXVKSzVyPUeuNFQ2OTJizszN	MlvjV2FPT1KHUh?=
KM-H2	MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLiTVhKSzVyPUeuNVg1PTdizszN	NXfDdZBrW0GQR2LFVi=>
NCI-H1436	MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDoTVg1UUN3ME23MlY6QTN{IN88US=>	M1rUT3NCVkeURWK=
IA-LM	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUG0dI01UUN3ME23Mlg2QSEQvF2=	NX7sNIJGW0GQR2LFVi=>
NCI-H526	NXjDfnhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHnT\|ZXUUN3ME24MlI2PjN5IN88US=>	M{T4enNCVkeURWK=
GCIY	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3Xs[GlEPTB;OD6zOlk3PSEQvF2=	MVTTRW5IWkWU
CP67-MEL	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRThwNUOyOkDPxE1?	NFvHbIpUSU6JUlXS
KALS-1	NETzRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rtemlEPTB;OD64N\|g2OSEQvF2=	M2XCVXNCVkeURWK=
NCI-H1770	M3i0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInPSJJKSzVyPUiuPVAzPjVizszN	NFnDd2lUSU6JUlXS
8-MG-BA	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17VOWlEPTB;OT6zNlg1PCEQvF2=	NI\FeXNUSU6JUlXS
KY821	MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDK[WJKSzVyPUmuO\|c1QDRizszN	MUfTRW5IWkWU
SNB75	Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfqcW5KSzVyPUGwMlA4PiEQvF2=	M4DhPXNCVkeURWK=
NCCIT	Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PVfWlEPTB;MUGuNFU5OiEQvF2=	M4K3XnNCVkeURWK=
SJSA-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTFzLkK4PVEh\|ryP	MUjTRW5IWkWU
LB373-MEL-D	NGDSSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDnZ4xIUUN3ME2xNU4{QDJ5IN88US=>	M3yybHNCVkeURWK=
TALL-1	MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;HU2lEPTB;MUGuOFA2QCEQvF2=	NGT4dnpUSU6JUlXS
NB69	M{\CWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DNSmlEPTB;MUGuO\|cxPSEQvF2=	NYrRTZA{W0GQR2LFVi=>
NCI-H1355	MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXz2WIl3UUN3ME2xNU46PDJ4IN88US=>	M4TaOXNCVkeURWK=
DMS-153	M3;mXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HHSmlEPTB;MUKuNFQzPiEQvF2=	NUf0SWpsW0GQR2LFVi=>
OPM-2	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEO2T5lKSzVyPUGyMlE2QTZizszN	M3;x[nNCVkeURWK=
NB1	M122Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fSZmlEPTB;MUKuNlkh\|ryP	NIXGbFBUSU6JUlXS
A3-KAW	NYTVemNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmG0TWM2OD1zMj6zNlM3KM7:TR?=	NHnHOpRUSU6JUlXS
NCI-H1882	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHGTWM2OD1zMj60NFY3KM7:TR?=	M3q2THNCVkeURWK=
KG-1	NVfGfVhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TGSmlEPTB;MUKuOlU1PSEQvF2=	NFuw[ZBUSU6JUlXS
LC4-1	M2nPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:wWXBIUUN3ME2xNk44PzB4IN88US=>	NWG0N\|RlW0GQR2LFVi=>
HCE-T	M4fseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTF\|LkCwOFkh\|ryP	NULKbFhmW0GQR2LFVi=>
NEC8	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TQcWlEPTB;MUOuNVA{QCEQvF2=	NYLwfWVqW0GQR2LFVi=>
IST-MEL1	M1nOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfQNGlKSzVyPUGzMlU4QDhizszN	NGG2SpJUSU6JUlXS
EW-3	MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2O2UWlEPTB;MUOuO\|QxOiEQvF2=	NYjkbG9mW0GQR2LFVi=>
CTB-1	NXLWSWlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PjOmlEPTB;MUSuNFMzQSEQvF2=	MUHTRW5IWkWU
LS-123	NFf2S2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXWxeYZpUUN3ME2xOE4yPTh6IN88US=>	Mn30V2FPT1KHUh?=
NCI-H1417	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTF2LkOwOVIh\|ryP	NX3iZnVDW0GQR2LFVi=>
MZ7-mel	M2K0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPITWM2OD1zND60OFM{KM7:TR?=	MoHiV2FPT1KHUh?=
JiyoyeP-2003	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTF3Lk[zNlYh\|ryP	NITpSJhUSU6JUlXS
ES6	NYrnZ\|BHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnURoJLUUN3ME2xOk4zOzZzIN88US=>	NEDVPI1USU6JUlXS
HH	NYH5b3dVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTF5LkG5OlMh\|ryP	NELBXmVUSU6JUlXS
SF539	MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLzOVFxUUN3ME2xO{46QTJ{IN88US=>	MXTTRW5IWkWU
Calu-6	NHXEOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\ab2lEPTB;MUmuNlM6KM7:TR?=	NWLIV3IxW0GQR2LFVi=>
SK-MM-2	M3HYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTF7LkW1OUDPxE1?	MUnTRW5IWkWU
IST-MES1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7MNpJKSzVyPUG5MlY3PjNizszN	Moj3V2FPT1KHUh?=
GI-ME-N	M4DwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;rRnJKSzVyPUG5MlgzOjdizszN	MWHTRW5IWkWU
CAL-148	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDLe\|ZKSzVyPUKwMlk6OzRizszN	NF;FUIlUSU6JUlXS
EVSA-T	NYH0[pdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvkd\|V5UUN3ME2yNU4yPDl7IN88US=>	NH;qSpVUSU6JUlXS
LP-1	NUOxVoV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3z1XmlEPTB;MkGuN\|Q{OiEQvF2=	Mof2V2FPT1KHUh?=
BOKU	M2PRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NES5Ro5KSzVyPUKxMlQ2OzNizszN	M{K0PXNCVkeURWK=
KLE	M{XKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjJ[nZKSzVyPUKyMlE6ODNizszN	MXrTRW5IWkWU
LB831-BLC	NYflXYlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfTcnhKSzVyPUK1MlE2OjZizszN	NWHKS4FJW0GQR2LFVi=>
NCI-H889	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLaWnp6UUN3ME2yOU4yQTNzIN88US=>	MV7TRW5IWkWU
REH	NUfyfpN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\iW3BKSzVyPUK1MlQ3PzFizszN	NGj6fZRUSU6JUlXS
KP-N-RT-BM-1	NVfXZ\|EyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\DflVKSzVyPUK1MlQ4PTJizszN	NIPTZYNUSU6JUlXS
MPP-89	NVOxTGZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXkTWM2OD1{NT61N\|E1KM7:TR?=	NFrNfY5USU6JUlXS
no-11	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTJ3Lke0O{DPxE1?	NF\BdFdUSU6JUlXS
NCI-H748	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTJ3Lke2Nlch\|ryP	MWnTRW5IWkWU
LB2518-MEL	NGDTfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTJ5LkG3O\|Mh\|ryP	NU\4RZR2W0GQR2LFVi=>
TGBC1TKB	NH;lPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHUW\|JKSzVyPUK3MlU2QDVizszN	NWLqbXNEW0GQR2LFVi=>
MHH-PREB-1	M3HvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\xV5hKSzVyPUK4MlA4OzRizszN	M4TTcXNCVkeURWK=
MZ2-MEL	MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfsSZpGUUN3ME2yPE43OTR\|IN88US=>	Mke2V2FPT1KHUh?=
U-266	NHn2W5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfQeG96UUN3ME2yPE43OzZ4IN88US=>	MoDEV2FPT1KHUh?=
SNU-C1	M2q0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXezcnF5UUN3ME2yPE46PDNizszN	NH6zUZdUSU6JUlXS
SW962	M1vV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTNyLkK3OFch\|ryP	MYXTRW5IWkWU
Raji	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DlO2lEPTB;M{CuOVU6OiEQvF2=	MW\TRW5IWkWU
KNS-42	M{nBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTNyLki5OVYh\|ryP	NEn0PVJUSU6JUlXS
LB996-RCC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIWxOlRKSzVyPUOxMlE4ODJizszN	M4CzWnNCVkeURWK=
CHP-126	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTNzLkG5PFQh\|ryP	NFfmc3pUSU6JUlXS
RXF393	NWjhRYN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;QTWM2OD1\|Mj60PVch\|ryP	Ml\CV2FPT1KHUh?=
COLO-684	NXLGfJJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\SV2lEPTB;M{KuOlQ{QCEQvF2=	MWXTRW5IWkWU
A704	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYH6SpptUUN3ME2zN{42PTN6IN88US=>	M{f2WnNCVkeURWK=
A253	M3fsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjuTWM2OD1\|Mz61PFUzKM7:TR?=	NEHrZ3lUSU6JUlXS
KNS-81-FD	M3WxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWr2W4JMUUN3ME2zOE42PDV4IN88US=>	NYflOHdUW0GQR2LFVi=>
TE-441-T	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHHTWM2OD1\|ND62N\|cyKM7:TR?=	MlS5V2FPT1KHUh?=
HCC2157	M1P3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHP1V2FKSzVyPUO1MlQ3OTlizszN	M2jCTnNCVkeURWK=
ES3	M{jjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHmTWM2OD1\|Nj62O\|Uh\|ryP	NIDLXpJUSU6JUlXS
NCI-H1155	NHnyfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLuOJFDUUN3ME2zO{45OTVizszN	M4LqUXNCVkeURWK=
SNU-C2B	NHLYVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XaNWlEPTB;M{iuNVY2PCEQvF2=	M3K1OnNCVkeURWK=
JAR	NIPlNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDCTWM2OD1\|OD6yOFQ6KM7:TR?=	MYPTRW5IWkWU
GDM-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH70WmRKSzVyPUO4MlkyOTZizszN	NH24XIFUSU6JUlXS
KU812	NGHsTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTRzLkWwO{DPxE1?	M3P1dHNCVkeURWK=
BC-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkK1TWM2OD12Mj62O\|MyKM7:TR?=	M{TQR3NCVkeURWK=
GI-1	M3rnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4ftSWlEPTB;NEKuPVE6OiEQvF2=	NXix[JYyW0GQR2LFVi=>
NCI-H1694	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnKVmt4UUN3ME20OE46PDd{IN88US=>	NVGyTYh5W0GQR2LFVi=>
DG-75	NXfSeItFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTR3LkG1O\|ch\|ryP	Mk[zV2FPT1KHUh?=
COR-L88	NWjNXndtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnMe2VwUUN3ME20OU4zPzd6IN88US=>	NH[yXoNUSU6JUlXS
LS-513	NWfhTIlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHGPWVKSzVyPUS1MlkyPTZizszN	NFjQXohUSU6JUlXS
HD-MY-Z	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIC2b5FKSzVyPUS2MlQ3OTJizszN	MY\TRW5IWkWU
L-363	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTR4Lki4NUDPxE1?	NVHCSoxyW0GQR2LFVi=>
TE-6	M37EU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fE[GlEPTB;NEiuOFQ3KM7:TR?=	NETDdWRUSU6JUlXS
NCI-H345	Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn22TWM2OD12OD60Olgh\|ryP	NHLsSFVUSU6JUlXS
TE-5	M1XhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEn0W4lKSzVyPUS5MlcyOThizszN	NXXRcWw3W0GQR2LFVi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DLK / p-MKK7 / MKK7 / p-JNK / JNK ; PubMed: 23431148 Proc Natl Acad Sci U S A Western blot of the DLK pathway members in RGCs (retinal ganglion cells) 4 h after immunopanning in the presence of 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, or 2 μM tozasertib. p-AURKA / AURKA / Survivin ; PubMed: 28218735 Oncogenesis BGC823 cells were incubated with indicated doses of VX-680 for 24 h before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means±s.e.m. of the ratios of Survivin to GAPDH. YAP; PubMed: 31160567 Cell Death Dis Western blot analysis of YAP protein level in A549 cells treated with indicated doses of VX-680 for 24 h. p-AKT / p-GSK3β / Cleaved caspase-3 / Cleaved PARP ; PubMed: 21600017 J Transl Med NB4-R2 cells were collected, lysed and subjected to Western blot analysis with cleaved caspase-3, cleaved-PARP, pAkt-1 (Ser473), pGSK-3β (Ser9) specific antibodies. GAPDH was used as a loading control. Data shown is a representative of three independent experiments.	23431148 28218735 31160567 21600017
Immunofluorescence	α-tubulin / Aurora-A ; PubMed: 21600017 J Transl Med The morphology of mitotic spindle was shown by immunofluorescence staining with anti-α-tubulin antibody and anti-Aur-A antibodies. Microtubules were stained as green, Aur-A protein as red, and nucleus as blue.	21600017
Growth inhibition assay	Cell viability; PubMed: 21600017 J Transl Med VX-680 significantly suppresses the proliferation in a number of leukemic cell types. OCI-AML3, NB4, HL-60 and ML-1 cells were incubated with increasing doses of VX-680 (1, 2, 5 and 10 nM) for 24 hr. Cell viability was measured by MTT assay. Data summarized three independent experiments, p < 0.05, *p < 0.01, compared to control.	21600017

In vivo

VX-680 gives rise to a marked decrease in tumor size in a human AML (HL-60) xenograft model. In mude mice treateed with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d. i.p.) for 13 days, mean tumor volumes are reduced by 98%. Tumor growth decrease is dose dependent and significant at a dose of 12.5 mg/kg b.i.d. VX-680 is well tolerated, with a small decrease in body weight observed only at the highest dose. VX-680 also triggers tumor regresson in pancreatic and colon xenograft models. VX-680 also displays potent antitumor activity when infused i.v. in mude rats bearing established HCT116 tumors. A higher dose of VX-680 (2 mg/kg/h) improves efficacy with a 56% decrease in mean tumor volume. ^[1]

Protocol

Kinase Assay: ^[3]	- Collapse Kinase inhibition assays: The consumption of ATP is coupled via the pyruvate kinase/lactic dehydrogenase enzyme pair to the oxidation of NADH, which can be monitored through the decrease in absorption at 340 nm. Reactions contains 100 mM Tris (pH 8), 10 mM MgCl₂, 2.2 mM ATP, 1 mM phosphoenolpyruvate, 0.6 mg/mL NADH, 75 units/mL pyruvate kinase, 105 units/mL lactate dehydrogenase, and 0.5 mM substrate peptide (sequence: EAIYAAPFAKKK). Reactions (75 μL) are started by adding sufficient kinase to bring the reactions to 30 nM kinase concentration and the decrease in absorbance is monitored over 30 minutes at 30°C in a microtiter plate spectrophotometer. Inhibitory constants are obtained through addition of 3.75 μL VX-680 in 100% DMSO or DMSO alone. Ki values are calculated as follows, K _i = IC50 / (1 + [S]/K_d), where [S] = [ATP] = 2.2 mM, and K_d (of ATP to Abl) = 70 μM. These values are calculated assuming a K_d (ATP) of 70 μM for wild type and H396P Abl kinase domain.
Cell Research: ^[2]	- Collapse Cell lines: CAL-62 cells Concentrations: 5-500 nM Incubation Time: 4 days Method: The CAL-62 cells are cultured in the absence (dimethyl sulfoxide, DMSO) or the presence of 500 nM VX-680 for different periods of time (1-5 days). The dose-dependent effects of VX-680 on cell proliferation are evaluated by treating the different ATC cells for 4 days with different concentrations of the Aurora inhibitor (5–500 nM). The cells are pulse labeled with 30 mM BrdU for 2 hours before the end of the incubation time. The BrdU incorporation is analyzed by means of a colorimetric immunoassay using the cell proliferation ELISA kit. The results from VX-680-treated cells are compared with those observed in control cells and expressed as a fold of variation versus control. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female athymic NCr-nu mice bearing HL-60 leukemia cells Dosages: 50 mg/kg, 75 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Cheetham GM, et al. Cancer Lett. 2007, 251(2), 323-329.

- Collapse

Solubility (25°C)

In vitro	DMSO	93 mg/mL (200.17 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Molecular Weight	464.59
Formula	C₂₃H₂₈N₈OS
CAS No.	639089-54-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=CC(=NN1)NC2=CC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)C4CC4)N5CCN(CC5)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Pan Aurora Kinase Inhibitors

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
Pan Aurora Kinase Inhibitors

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
Most Potent Aurora Kinase Inhibitor

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
Aurora Kinase Inhibitor in Clinical Trial

Alisertib (MLN8237) : Phase III for Relapsed/Refractory Peripheral T-Cell Lymphoma.
Classic Aurora Kinase Inhibitor

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

Related Aurora Kinase Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007) is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 is associated with an increase in p38 activation and may induce p38-dependent apoptosis/senescence. ML141 also protects neuroblastoma cells from metformin-induced apoptosis.
Alisertib (MLN8237)

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Alisertib induces cell cycle arrest, apoptosis and autophagy. Phase 3.

Features:First orally available inhibitor of Aurora A.
Barasertib (AZD1152-HQPA)

Barasertib (AZD1152-HQPA, AZD2811) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Danusertib (PHA-739358)

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Danusertib induces apoptosis, cell cycle arrest, and autophagy. Phase 2.
ZM 447439

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

Features:An Aurora selective ATP-competitive inhibitor.
MLN8054

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.
MK-5108 (VX-689)

MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. MK-5108 (VX-689) induces autophagy. Phase 1.
Aurora A Inhibitor I (TC-S 7010)

Aurora A Inhibitor I (TC-S 7010) is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B. Aurora A Inhibitor I (TC-S 7010) triggers apoptosis through the ROS-mediated UPR signaling pathway.

Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

Tozasertib (VX-680, MK-0457)